New Drugs in Oncology

June 1 from 12:30 PM-5:00 PM and June 2 from 7:30 AM-11:00 AM
McCormick Place, Room S100a

Seminar Description

The New Drugs in Oncology Seminar will focus on the theoretical and practical aspects of both recently approved drugs and those on their way to approval. Topics covered will include mechanisms of action, administration, toxicity and side-effect management, and use in the clinic.  

This seminar is approved for physician and pharmacist credits. Additional information regarding CE credits is listed below.

Seminar Committee

View Seminar Committee Disclosures

George W. Sledge, MD, FASCO​ (Co-Chair)​
Stanford University Medical Center

Anthony W. Tolcher, MD (Co-Chair)​
The START Center for Cancer Care

Howard A. Burris, MD, FASCO​
Sarah Cannon Research Institute

Bruce E. Hillner, MD, FASCO
Virginia Commonwealth University

Shivaani Kummar, MD, FACP
Stanford University Medical Center

Patricia LoRusso, DO
Yale University

Richard Pazdur, MD
U.S. Food and Drug Administration

Lee S. Rosen, MD
UCLA Santa Monica Hematology-Oncology

Howard McLeod, PharmD
H. Lee Moffitt Cancer Center and Research Institute

Seminar Agenda

Day 1: Thursday, June 1, 2017: 12:30 PM – 5:00 PM

12:30 PM – 1:00 PM Lunch
1:00 PM – 2:20 PM

Session 1: Basket Trials as a New Model for Drug Development: A Discussion

Anthony Tolcher, MD - Chair/Moderator


Keith Flaherty, MD
Massachusetts General Hospital
Basket Trials as a New Model for Drug Development - Point


Emiliano Calvo, MD, PhD
START Madrid Group
Basket Trials as a New Model for Drug Development - Counterpoint


Stanley Hamilton, MD
The University of Texas MD Anderson Cancer Center
Practical Challenges and the Direction the Field is Going


Panel Question and Answer

2:20 PM – 2:35 PM


2:35 PM – 3:45 PM

Session 2: Assessing the Value of the NCI Cancer Therapy Evaluation Program (CTEP)

Howard A. Burris III, MD - Chair/Moderator
Sarah Cannon Research Institute


Geoffrey Shapiro, MD, PhD
Dana-Farber Cancer Institute
Assessing the Value of the NCI Cancer Therapy Evaluation Program​ - Point


Anthony Tolcher, MD
Assessing the Value of the NCI Cancer Therapy Evaluation Program​ - Counterpoint


Panel Question and Answer

3:45 PM – 5:00 PM

Session 3: Combination Therapies

Bruce Hillner, MD - Chair
Virginia Commonwealth University


James Gulley, MD, PhD
National Cancer Institute
Taking the Pulse of Immunotherapy: Current Status and Future Possibilities


Igor Puzanov, MD, FACP
Roswell Park Cancer Institute
Evaluation of Immunotherapy and Novel Combinations in Oncology


Omid Hamid, MD
The Angeles Clinic and Research Institute
Identifying Appropriate Endpoints for Combination Therapy Trials


Panel Question and Answer


Day 2: Friday, June 2, 2017: 7:00 AM – 11:00 AM

7:00 AM – 7:30 AM Breakfast
7:30 AM – 8:55 AM

Session 4: New Drugs in Oncology and Their Incorporation into the Clinic 

George W. Sledge, MD, FASCO​ - Chair
Stanford University Medical Center


Gabriel N. Hortobagyi, MD, FACP
The University of Texas MD Anderson Cancer Center
Ribociclib for Breast Cancer


Kathleen N. Moore, MD
University of Oklahoma Health Sciences Center
Rucaparib for Ovarian Cancer


Fabrice Barlesi, MD, PhD
Aix-Marseille University, Assistance Publique Hopitaux de Marseille
Atezolizumab for Metastatic Non-small Cell Lung Cancer (NSCLC)

Panel Question and Answer

8:55 AM – 9:10 AM Break
9:10 AM – 11:00 AM

Paul Nghiem, MD, PhD
University of Washington
Avelumab for Merkel Cell Carcinoma


Toni K. Choueiri, MD
Dana-Farber Cancer Institute and Brigham and Women's Hospital
Cabozantinib for Renal Cell Carcinoma


Matthew Steven Davids, MD, MMSc
Dana-Farber Cancer Institute/Harvard Medical School
Venetoclax for Chronic Lymphocytic Leukemia (CLL)


Sagar Lonial, MD, FACP 
Winship Cancer Institute
Daratumumab Combinations for Multiple Myeloma


Panel Question and Answer


Accreditation and Designation Statements

In support of improving patient care, the American Society of Clinical Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Society of Clinical Oncology designates this live activity for a maximum of 7.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACPE Credit Designation Statement – Pharmacists

This activity has been approved for 7.5 contact hours (.75 CEUs) under the ACPE universal activity number 0628-0000-17-005-L01-P.
Activity type: Knowledge.                                                                                            
The activity start date for continuing pharmacy credit eligibility is 06/01/17, with an expiration date of 06/02/17. 
The American Association of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by the ACCME or a recognized state medical society. PAs may receive a maximum of 7.5 Category 1 credits for completing this activity.

All other attendees are welcome to submit a request for a Certificate of Participation, through the submission process, which may enable nonphysicians to apply their participation toward re-licensure. Please note, however, that all final decisions regarding the awarding of credits will be made by the licensing organization to which the credits were submitted. 

Target Audience

The 2017 New Drugs in Oncology Seminar is designed for the cancer care team; credit is offered for physicians and phamacists, but all are encouraged to participate, as they may be able to apply for credit through their own licensing organization.

Learning Objectives

Upon participation in this activity, attendees will be able to:

  • Review and inform oncology prescribers regarding the safe dosing and use of recently approved agents, along with the considerations for appropriate inclusion in a treatment plan for patients with cancer.
  • Evaluate the appropriateness of how and when to integrate new therapies into clinical care.
  • Discuss the use of immune monitoring strategies for the identification of relevant biomarkers and the evaluation of combination therapy strategies to improve clinical outcomes.
  • Review the pros and cons of the Cancer Therapy Evaluation Program (CTEP) in the selection of clinical research for National Cancer Institute (NCI) sponsorship.
  • Describe how the use of basket studies focused on a single genetic mutation can be effective across multiple cancer types.

Disclaimer/Unlabeled Usage Statement         

The information presented is that of the contributing authors and does not necessarily represent the views of the American Society of Clinical Oncology and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated. Therefore, before prescribing any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions and adverse effects.

Commercial Support

ASCO and the Conquer Cancer Foundation gratefully acknowledge the following organizations for their support of the 2017 New Drugs in Oncology Seminar:

Astellas Novartis Oncology
Pfizer Oncology